HCV New Drugs

This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.

Risk Of Developing Liver Cancer After HCV Treatment

  • Home
  • Newly Diagnosed With Hep C? Or Considering Treatment?
  • All FDA Approved Drugs To Treat Hepatitis C
  • Hepatitis C Genotypes and Treatment
  • Mavyret (glecaprevir/pibrentasvir)
  • Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
  • Epclusa® (Sofosbuvir/Velpatasvir)
  • Harvoni® (Ledipasvir/Sofosbuvir)
  • VIEKIRA XR/VIEKIRA Pak
  • Zepatier(Elbasvir/Grazoprevir)
  • Cure - Achieving sustained virologic response (SVR) in hepatitis C
  • HCV Liver Fibrosis
  • FibroScan® Understanding The Results
  • HCV Cirrhosis
  • Staging Cirrhosis
  • HCV Liver Cancer
  • Risk Of Developing Liver Cancer After HCV Treatment
  • Treating Elderly HCV Patients
  • Fatty Liver Disease: NAFLD/NASH
  • Current research articles on ailments that may be related to HCV
  • Is There A Natural Way To Improve Liver Fibrosis?  
  • Can Food Or Herbs Interact With Conventional Medical Treatments?

Monday, January 14, 2013

Watch: Hepatitis And A Fatty Liver- Huffington Post


Source
http://videos.huffingtonpost.com/healthy-living/hepatitis-and-a-fatty-liver-517632446

In Todays News
Drs. Oz and Roizen: Kick start your liver-lovin' lifestyle
Liver damage severity in obese children affected by ethnicity, genetic polymorphisms
Posted by HCV New Drugs at Monday, January 14, 2013
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
File Under Fatty Liver, HCV News, video

No comments:

Post a Comment

Newer Post Older Post Home
View mobile version
Subscribe to: Post Comments (Atom)

https://feedburner.google.com/fb/a/mailverify?uri=HcvNewDrugsAndLiverHealth
View Feed

Subscribe 

  • ►  2020 (3)
    • ►  January (3)
  • ►  2019 (112)
    • ►  December (1)
    • ►  March (11)
    • ►  February (43)
    • ►  January (57)
  • ►  2018 (689)
    • ►  December (18)
    • ►  November (87)
    • ►  October (62)
    • ►  September (46)
    • ►  August (36)
    • ►  July (23)
    • ►  June (44)
    • ►  May (60)
    • ►  April (103)
    • ►  March (85)
    • ►  February (59)
    • ►  January (66)
  • ►  2017 (898)
    • ►  December (42)
    • ►  November (56)
    • ►  October (104)
    • ►  September (81)
    • ►  August (74)
    • ►  July (90)
    • ►  June (52)
    • ►  May (53)
    • ►  April (105)
    • ►  March (94)
    • ►  February (85)
    • ►  January (62)
  • ►  2016 (525)
    • ►  December (15)
    • ►  November (73)
    • ►  October (43)
    • ►  September (53)
    • ►  August (41)
    • ►  July (42)
    • ►  June (28)
    • ►  May (54)
    • ►  April (60)
    • ►  March (37)
    • ►  February (40)
    • ►  January (39)
  • ►  2015 (546)
    • ►  December (27)
    • ►  November (53)
    • ►  October (46)
    • ►  September (41)
    • ►  August (42)
    • ►  July (24)
    • ►  June (49)
    • ►  May (53)
    • ►  April (59)
    • ►  March (59)
    • ►  February (37)
    • ►  January (56)
  • ►  2014 (613)
    • ►  December (29)
    • ►  November (64)
    • ►  October (62)
    • ►  September (17)
    • ►  August (51)
    • ►  July (28)
    • ►  June (38)
    • ►  May (73)
    • ►  April (87)
    • ►  March (60)
    • ►  February (45)
    • ►  January (59)
  • ▼  2013 (957)
    • ►  December (44)
    • ►  November (77)
    • ►  October (71)
    • ►  September (71)
    • ►  August (73)
    • ►  July (84)
    • ►  June (86)
    • ►  May (78)
    • ►  April (110)
    • ►  March (70)
    • ►  February (79)
    • ▼  January (114)
      • Target 'super-spreaders' to stop hepatitis C
      • Interferon free regimens for the “difficult to tre...
      • Liver Cancer-Phase III HEAT trial of Thermodox Fai...
      • Interferon May Be Harmful in Retreatment of Hepati...
      • HCC incidence increased in HIV/hepatitis coinfection
      • Vertex hepatitis C drug revenues plummet
      • Hepatitis Connect Presents An Interview With Alan ...
      • Hepatitis C - The Unspoken Epidemic
      • Cancer risk much greater among men
      • Janssen and Idenix - The Newest Hep-C Partnership
      • CDC-Foodborne Disease Outbreaks - United States, 2...
      • No Added Benefit for Chemo Beads in Liver Cancer
      • Pegylated interferon- Pegasys, PegIntron similarly...
      • Scientists Discover Process That Turns Normal Live...
      • Predicting survival among those aging with HIV inf...
      • National Hepatitis C Survey Prompts Call for All C...
      • Hepatitis C progress in pipeline-New drugs to trea...
      • Simeprevir, TMC647055 and IDX719 Phase II all-oral...
      • Weekend Reading-Is The HCV Pipeline Heading in the...
      • FDA warns of liver injury risk associated with hyp...
      • The Improving Landscape of HCV Therapy: The Opport...
      • TGIF HCV Rewind: Ribavirin induced anemia and New ...
      • The Age-Old Debate of Whether to Biopsy in HCV: My...
      • One in Six Chronic Hepatitis C Patients May Have a...
      • 2nd New York hospital warns of potential HIV, hepa...
      • Bristol Reaches $80 Million Deal to Settle Hepatit...
      • Reuters - Hepatitis C linked to ink
      • Detection of Hepatocellular Carcinoma at Advanced ...
      • HBV genotype C carries greater risk for HCC than o...
      • Current Prospects for Interferon-free Treatment of...
      • Healio Minute -Reason for most doctor visits 'skin...
      • Binge drinking can dramatically amplify damage to ...
      • 2013-Guide to Clinical Trials for People with Hepa...
      • Liver cirrhosis - Physiologic and laboratory corre...
      • Watch - Revitalizing the Dead Liver
      • Hepatitis C - New Ways to Study Genotypes 3 and 4
      • Hepatitis C - 8 Clinical Trials For: Sofosbuvir (G...
      • Futility rules defined for telaprevir-based HCV th...
      • Statins Are Associated With a Reduced Risk of Hepa...
      • HCV Weekly Rewind: IFN-free Trials, The Silent Pan...
      • The burden of hepatitis C in Europe from the patie...
      • Online tattoo and piercing kits could be spreading...
      • Hepatitis C-Sofosbuvir(GS-7977)/GS-5885 and Ribavi...
      • Faldaprevir (BI 201335) and BI 207127-Boehringer E...
      • Model assesses HCC risk according to age, platelet...
      • Medscape - Understanding Opioids: Part 2
      • HCV therapy for injection drug users
      • Early hepatocellular carcinoma – Is there such a t...
      • Harmful cells also aid liver repair
      • Bristol-Myers to Hold Talks On Settling Claims of ...
      • The Flu - A Family Affair?
      • Health care-related exposure linked to HCV, HBV in...
      • Analysis: Drug industry bets on new blockbusters i...
      • Reducing Risk for Mother-to-Infant Transmission of...
      • Comparative Effectiveness of Antiviral Treatment f...
      • Annals Of Internal Medicine: Screening for Hepatit...
      • Drugmakers suffer decline in trust, report says
      • Successful Clearance of Hepatitis C Virus Is Assoc...
      • Updated Practice Guideline: Treatment of Genotype ...
      • Generic HIV treatment strategy could save nearly $...
      • Watch: Hepatitis And A Fatty Liver- Huffington Post
      • Hepatitis C: a projection of the healthcare and ec...
      • CCO: Expert analysis of the most important new dat...
      • Buffalo VA Medical Center - Remote but possible th...
      • TGIF HCV Weekely Rewind- Part 3: So You Think You’...
      • Patients with HCV and F1 and F2 fibrosis: treat no...
      • Telaprevir - Analysis of geno 2 and 3 hepatitis C ...
      • Roche Scientists Uncover Unexpected Enzyme Activit...
      • Investment Commentary Hepatitis C Market-Sofosbuvi...
      • Hepatitis C Toll Free Helplines and Online Support
      • NQF Endorses Infectious Disease Measures
      • Acetaminophen overdose a danger during flu season
      • Decline in available liver transplants expected
      • Researchers Foresee New Treatments and Diagnostics...
      • Nucleotide Polymerase Inhibitors - The Search For ...
      • Inovio to Initiate Clinical Trial for its Hepatiti...
      • Improvement of neurocognitive function in responde...
      • Patients younger than 40 with hepatitis C genotype...
      • FDA Grants Orphan-Drug Designation for Novel Terli...
      • Efficacy of the retreatment of hepatitis C virus i...
      • Teens Susceptible to Hepatitis B Infection Despite...
      • Gilead signs antibody deal with MacroGenics
      • Secondary infections increase mortality in hospita...
      • Off Topic:Exploring the microbes that inhabit our ...
      • Patients receiving opioid maintenance treatment in...
      • S.A. doctors find faster, better way to beat hepat...
      • A New Tool for HCV Patients With Low Platelet Counts
      • High alcohol consumption increased risk for hepato...
      • Gilead's lead 'nuc' sofosbuvir anchoring what coul...
      • Hepatitis C - Achillion Reports Interim Results on...
      • NIH investigators discover new gene that affects c...
      • Gilead Update - 2nd Phase 3 Study of Sofosbuvir a...
      • Hepatitis C: Vertex's strategy in hepatitis C is t...
      • HCV: second-generation protease inhibitors
      • New therapeutic strategies in HCV: polymerase inhi...
      • Hepatitis C-Interferon free therapy with direct ac...
      • Treatment of viral hepatitis: a new era
      • Competition affects who gets a liver transplant
      • Screening combo finds HCC in cirrhosis patients
      • Australia-Advocates slam delay in listing hepatiti...
  • ►  2012 (1293)
    • ►  December (80)
    • ►  November (114)
    • ►  October (114)
    • ►  September (95)
    • ►  August (100)
    • ►  July (120)
    • ►  June (125)
    • ►  May (145)
    • ►  April (134)
    • ►  March (88)
    • ►  February (64)
    • ►  January (114)
  • ►  2011 (1574)
    • ►  December (75)
    • ►  November (81)
    • ►  October (70)
    • ►  September (83)
    • ►  August (142)
    • ►  July (157)
    • ►  June (166)
    • ►  May (128)
    • ►  April (160)
    • ►  March (176)
    • ►  February (140)
    • ►  January (196)
  • ►  2010 (672)
    • ►  December (184)
    • ►  November (236)
    • ►  October (223)
    • ►  September (29)

Labels

(Sofosbuvir) now Sovaldi 2017 Digestive Disease Week 2017 EASL-AASLD joint meeting on Alcohol related Liver Disease 2017 World Hepatitis Summit 2017 - International AIDS Society (IAS) 2017 British and Irish Gastroenterology meeting 2017 Conference on Retroviruses and Opportunistic Infections (CROI) 2017 CROI 2017 Drug-Induced Liver Injury Conference 2017 EASL Clinical Practice Guidelines on the management of hepatitis B virus infection 2017 Gastroenterological Society of Australia Australian Gastroenterology Week 2017 GUIDE TO HEPATITIS C TESTING 2017 IDWeek 2017 International Conference on Viral Hepatitis (ICVH) 2017 International Liver Cancer Association Annual Conference 2017 International Liver Congress 2017 International Liver Transplantation Society Consensus Statement on Hepatitis C Management in LT Candidates 2017 Practice update for managing patients cured of HCV infection 2017 Summary International Liver Congress 2017 TAG Pipeline Report 2017 The 68th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2017 2017 World Hepatitis Day 2017-10th Paris Hepatitis Conference 2017-APASL 2017-Hepatitis A to E 2017-National Strategy for the Elimination of HBV HCV 2017-WHO Essential Medicines List 2017-World Hepatitis summit 2017/WHO Global hepatitis report 2017/WHO guidelines on testing for chronic HBV and HCV infection 2018 2018 - Eliminating Hepatitis C in England 2018 - adult 2018 - Conference on Retroviruses and Opportunistic Infections (CROI) 2018 - International Liver Congress 2018 - updated and evidence-based review about Hepatocellular Carcinoma 2018- 11th Paris Hepatology Conference 2018-Diagnosis & management of hepatitis C infection 2018-WHO Access to hepatitis C treatment AASLD 2017 updated hepatitis C practice guidelines Acetaminophen Safety addiction Adherence to therapy AL-335 alcohol consumption anemia antidepressants arthritis ascites bath salts-spice Bavituximab BCX5191 Behind the Headlines Big Pharma blood scandal Brain Canada cancer CC-31244 CDC children treating HCV chronic fatigue chronic liver failure chronic pain cirrhosis cirrhosis-complications cirrhosis-Vibrio vulnificus-raw oysters clinical trials coffee Colloidal silver colonoscopy compensated cirrhosis Complementary and Alternative Medicine COPD Counterfeit drugs Cryoglobulinemia Daklinza(Daclatasvir) Daklinza(Daclatasvir) with sofosbuvir decompensated cirrhosis Dental Depression diabetes diabetes-insulin resistance Digestion disease progression donation Drug Assistance Programs encephalopathy endoscopy Epclusa® Epclusa® (Sofosbuvir/Velpatasvir) fatigue Fatigue-Cognitive Function-Sleep Quality Fatty Liver Fatty liver CF102 Fatty Liver-RP103 FDA fibromyalgia Foodborne illness gallstones Generic sofosbuvir-based geno1 geno2 geno3 geno4 geno5 geno6 genotype test genotypes mixed genotypes;All Glecaprevir/Pibrentasvir Grazoprevir/Elbasvir (MK-5172/MK-8742) plus sofosbuvir grazoprevir/elbasvir (MK-5172/MK-8742) grazoprevir/elbasvir / MK-3682 grazoprevir/MK-8408/MK-3682 green tea GS-7977 now Sofosbuvir GS-7977 now Sofosbuvir and simeprevir (TMC435) GS-7977 now sofosbuvir / GS-5885 now ledipasvir GS-7977 now Sofosbuvir off label use GS-7977 now Sofosbuvir Plus Riba GS-7977 now Sofosbuvir-FDA Review GS-7977 now Sofosbuvir/BMS-790052 now Daclatasvir HALT-C Harvoni patient assistance Harvoni® (Ledipasvir/Sofosbuvir) hav hav vaccine hbv hbv vaccine HBV/HCV dual infection HCC during and after direct-acting antiviral therapy in patients with hepatitis C HCV Australia HCV agents/drug interactions HCV Awareness HCV Awareness-screening strategies HCV Baby Boomers HCV cardiovascular disease HCV diet HCV generics HCV News-monthly rewind HCV News-weekly rewind HCV next HCV pregnancy HCV research HCV Self-management HCV symptoms HCV tests HCV transmission FAQ HCV Vaccine HCV vaccine GI-5005 HCV Vaccine-TG4040 (MVA-HCV) HCV Worldwide HCV Worldwide Asia Australia Egypt HCV Worldwide-Egypt HCV Worldwide-Europe Canada Israel HCV-Editorial HCV-Education HCV-elderly HCV-Insulin resistance HCV-Statins HCV/HBV/HIV special populations Healthy you hepatologist herb herb-kava HEV History of HCV HIV HIV-children hiv/hbv-coinfection HIV/HCV IL28B Investment News HCV Drugs IV drug use Joint pain kratom Lichen Planus Liver Abscess liver biopsy liver cancer Liver Cancer Treatment liver cancer treatment-radiofrequency ablation (RFA) liver cancer/sorafenib Liver Cysts liver disease Liver Fibrosis liver function tests liver health Liver Injury Dietary Supplements Liver Pain liver/anatomy lymphoma marijuana MAVIRET (glecaprevir/pibrentasvir) Mavyret (glecaprevir/pibrentasvir) Medicaid medical tourism Mediterranean diet melatonin Memorial Wall Men and HCV mental health Milk thistle Miracle Mineral Solution-MMS Miravirsen miRNAs MK3(MK-3682/grazoprevir/ruzasvir1) Morbidity-SVR Mortality Mother to a Child Transmission Muscle Cramps Neutropenia HCV Treatment newly diagnosed newsletters Nonalcoholic Steatohepatitis (NASH) noninvasive tests for fibrosis nonresponders NSAID null responders OLYSIO™ (Simeprevir) and Sovaldi (Sofosbuvir) OLYSIO™(Simeprevir) containing regimens ombitasvir/paritaprevir/ ritonavir (OBV/PTV/r) opioid addiction Origin Of Hepatitis Other Conditions Related To HCV Other Conditions Related To HCV-Vasculitis Other Health News OTHER INFECTIOUS DISEASE partial responders Pediatric liver disease Pharmaceuticals PHYSICAL FINDINGS SUGGESTIVE OF CIRRHOSIS platelets Porphyria Cutanea Tarda (PCT) Post Treatment Post Treatment Symptoms probiotics procrit Questions About HCV rash Rebuttal over Cochrane Review of DAAs recall regeneration regenerative Medicine relapse resistance to protease inhibitors response-guided therapy restless legs syndrome ribavirin salt Seasonal Flu Vaccine selenium side effects side effects-direct-acting antivirals silibinin silymarin Simeprevir Simeprevir and Daclatasvir Simeprevir now Olysio Simeprevir now Olysio and Daclatasvir Simeprevir now Olysio FDA Approved Small fiber neuropathy Sofosbuvir/Cost Sorafenib Sovaldi resistance sphincter of Oddi spleen SPONTANEOUS CLEARANCE Starting HCV Treatment STAT-C stem cell tourism stem cells stigma supplements support support-hotline Surgery in liver disease svr svr durability SVR24-SVR12-SVR4 Tamiflu Tattoos Technivie TGIF-News Review The natural history of hepatitis C thyroid Timeline Hepatitis toxicity transmission transmission-needlestick transplant transplant-MELD Treat All tylenol upper abdominal pain varices veterans Veterans Affairs video Viekira Pak Viekira Pak Prescribing Information Viekira XR VIEKIRAX viral load vitamin A vitamin B12 vitamin D vitamin E Vitamin E-TE/TCP supplements vitamin k vitamins Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) weekend reading wellness women zinc

Search This Blog
Contact hcvnewdrugs@gmail.com

Helpful Links
HCV Education
Research Articles
Fibrosis
Cirrhosis
Liver Cancer
Liver Transplants
Fatty Liver Disease
HCV-elderly
Possible Side Effects Of HCV Therapy
Other Conditions Related To HCV
HCV Genotypes/treatment
HCV Newsletters
Premier Hepatitis C Websites

The above links offer data about interferon-free regimens approved to treat HCV, with learning activities,  editorials, and tips from patient bloggers who understand the ups and downs of liver disease, in addition to a list of outstanding hepatitis C websites, blogs and support forums.

 On Twitter
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading articles about the treatment and management of hepatitis C.

The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"
Latest Update Feb 12, 2019 
Lancet Study: 
Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C 
These findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term HCV-related morbidity and mortality. They also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection.

The Controversy 
Rebuttal over Cochrane Review of DAAs 
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage.

Simple theme. Powered by Blogger.

FAIR USE NOTICE:

If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas.

It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes.

The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice